A fairly neutral result IMHO.. EBITDA loss for H2 is the most encouraging data point here, given markets are forward looking this does provide a foundation for a solid half this year.
The company is annoyingly tight-lipped when it comes to remarking on anything forward looking.
They have also confirmed that sales last month were materially higher YoY:
The company did mention they expect a material improvement in sales from the increased reimbursement:
With all of this, combined with improving gross margins, pathway to profitability seems set in stone however likely another CR to get us there
Ann: Full Year Financial Results, page-30
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $4.299K | 22.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 68058 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 125711 | 4 |
View Market Depth
| Last trade - 10.38am 03/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |